Valuation: Enzymatica AB

Market Cap 432M 384M 359M 325M 614M 41.65B 619M 4.31B 1.68B 21.25B 1.62B 1.59B 68.31B P/E 2024
-5.73x
P/E 2025 -8.89x
Enterprise Value 400M 355M 332M 301M 569M 38.56B 573M 3.99B 1.55B 19.67B 1.5B 1.47B 63.23B EV / Sales 2024
5.88x
EV / Sales 2025 7.96x
Free-Float
56.66%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 01/02/2026
Director of Finance/CFO - 13/04/2026
Chief Tech/Sci/R&D Officer - 27/08/2026
Director TitleAgeSince
Chairman 58 15/02/2016
Chairman 64 19/12/2016
Director/Board Member 71 19/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
+2.32%+3.00% - - 43.02M
+1.33%-2.29%+36.98%+104.79% 1,019B
+0.79%-4.54%+35.75%+62.03% 610B
+0.40%+1.71%+16.33%+80.64% 470B
+1.23%-5.22%+59.33%+36.20% 344B
+0.26%+0.14%+21.29%+40.99% 336B
+0.60%-3.09%+10.76%+32.59% 266B
+1.65%-3.78%-6.03%+9.29% 241B
-0.23%-5.15%+36.62%+50.24% 218B
-0.49%-4.91%+26.65%+92.47% 179B
Average +0.74%-3.63%+26.41%+56.58% 409.2B
Weighted average by Cap. +0.76%-3.51%+29.56%+67.10%

Financials

2024 2025
Net sales 45.58M 40.46M 37.86M 34.32M 64.81M 4.39B 65.28M 455M 177M 2.24B 171M 167M 7.21B 53.9M 47.85M 44.78M 40.59M 76.65M 5.2B 77.21M 538M 209M 2.65B 202M 198M 8.52B
Net income -53.18M -47.21M -44.18M -40.04M -75.62M -5.13B -76.17M -531M -206M -2.62B -200M -195M -8.41B -51.89M -46.06M -43.11M -39.07M -73.79M -5B -74.32M -518M -201M -2.55B -195M -191M -8.2B
Net Debt -73.01M -64.81M -60.65M -54.97M -104M -7.04B -105M -728M -283M -3.59B -274M -268M -11.54B -32.11M -28.5M -26.68M -24.18M -45.66M -3.1B -45.99M -320M -125M -1.58B -121M -118M -5.08B
Logo Enzymatica AB
Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.
Employees
-